Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gressenberger, P; Jud, P; Kovacs, G; Kreuzer, S; Brezinsek, HP; Guetl, K; Muster, V; Kolesnik, E; Schmidt, A; Odler, B; Adelsmayr, G; Neumeister, P; Brcic, L; Zenz, S; Weber, K; Gary, T; Brodmann, M; Graninger, WB; Moazedi-Fürst, FC.
Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.
J Pers Med. 2021; 11(7): Doi: 10.3390/jpm11070600 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Gressenberger Paul Georg
Co-Autor*innen der Med Uni Graz
Adelsmayr Gabriel
Brcic Luka
Brezinsek Hans-Peter
Brodmann Marianne
Gary Thomas
Graninger Winfried
Gütl Katharina
Jud Philipp
Kielhauser Sonja
Kolesnik Ewald
Kovacs Gabor
Moazedi-Fürst Florentine
Nemecz Viktoria
Neumeister Peter
Odler Balazs
Schmidt Albrecht
Weber Kurt
Zenz Sabine

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Systemic sclerosis (SSc) is an intractable autoimmune disease characterized by vasculopathy and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) should be considered for the treatment of selected patients with rapid progressive SSc at high risk of organ failure. It, however, remains elusive whether immunosuppressive therapies such as rituximab (RTX) are still necessary for such patients after AHSCT, especially in those with bad outcomes. In the present report, a 43-year-old man with diffuse cutaneous SSc received AHSCT. Despite AHSCT, SSc further progressed with progressive symptomatic heart failure with newly developed concomitant mitral and tricuspid valve insufficiency, thus the patient started on RTX 8 months after AHSCT. Shortly after initiation of RTX, clinical symptoms and organ functions ameliorated subsequently. Heart valve regurgitations were reversible after initiation of RTX treatment. Currently, the patient remains in a stable condition with significant improvement of clinical symptoms and organ functions. Reporting about therapies after AHSCT in SSc is a very important issue, as randomized controlled trials are lacking, and therefore this report adds to evidence that RTX can be considered as a treatment option in patients with SSc that do not respond to AHSCT.

Find related publications in this database (Keywords)
systemic sclerosis
autologous hematopoietic stem cell transplantation
© Med Uni Graz Impressum